MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/mpg.0000000000003406

Медицинская библиотека · Journal of pediatric gastroenterology and nutrition · 2022

Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy.

El-Sayed Manal Hamdy, Ebeid Fatma S Elsayed, Zekri Abdel-Rahman, Massetto Benedetta, Kersey Kathryn, Zhang Fangqiu, Gaggar Anuj, Elsayed Walaa, El-Haddad Alaa

Клиническое исследование II фазыСтатьяПеревод в очереди

Аннотация

OBJECTIVES

In children with hematological malignancies, chronic hepatitis C virus (HCV) infection has been associated with more rapid liver disease progression and higher risk of malignancy relapse due to chemotherapy interruption. We evaluated the safety and efficacy of ledipasvir-sofosbuvir for 12weeks in these patients.

METHODS

In a phase 2, open-label study, at one site in Egypt, patients ages 12-<18years with chronic HCV genotype 1 or 4 infection undergoing maintenance chemotherapy for hematological malignancies received ledipasvir-sofosbuvir (90 mg/400 mg) once daily for 12weeks. The efficacy endpoint was sustained virologic response 12 weeks after treatment (SVR12). Safety was assessed by the incidence of adverse events and clinical and laboratory data, including HCV flares defined as alanine aminotransferase >3-fold increase from Day 1 and HCV RNA elevation >1 × log10 from Day 1.

RESULTS

Of the 19 adolescents enrolled and treated, median age was 14 years (range 12-17), 84% (16/19) were male, and all had HCV genotype 4 and were HCV treatment naive. All patients completed treatment and achieved SVR12 (19/19, 100%, 95% confidence interval, 82-100). Common adverse events were pyrexia (5/19, 26%), diarrhea (4/19, 21%), and headache (4/19, 21%). Three patients experienced serious adverse events of pneumonia (two patients), and osteoarthritis and diarrhea (one patient); none were considered related to study drug. No patient experienced HCV flares.

CONCLUSIONS

Ledipasvir-sofosbuvir was well-tolerated and efficacious in adolescents with chronic HCV genotype 4 and leukemia undergoing maintenance chemotherapy. These data support the use of this interferon and ribavirin-free regimen in adolescents with hematological malignancies.

Для цитирования: El-Sayed Manal Hamdy, Ebeid Fatma S Elsayed, Zekri Abdel-Rahman, Massetto Benedetta, Kersey Kathryn, Zhang Fangqiu, Gaggar Anuj, Elsayed Walaa, El-Haddad Alaa. Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy.. Journal of pediatric gastroenterology and nutrition. 2022. DOI: 10.1097/mpg.0000000000003406.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.